Special Issue "In Vitro and In Vivo Models of Colorectal Cancer for Clinical Application"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Trials of Cancer".

Deadline for manuscript submissions: 28 February 2021.

Special Issue Editors

Dr. Marta Baiocchi
Website
Guest Editor
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 199, Roma 00161, Italy
Interests: colorectal cancer; cancer stem cells; stem cells biobanks; high-throughput analysis; target-oriented therapies
Dr. Ann Zeuner
Website
Guest Editor
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 199, Roma 00161, Italy
Interests: cancer stem cells; colorectal cancer; breast cancer; quiescence; chemotherapy resistance

Special Issue Information

Dear Colleagues,

Recent years have witnessed an unprecedented expansion of therapeutic options for colorectal cancer (CRC), with several molecularly targeted agents now established in clinical practice. Moreover, many new approaches are currently under evaluation, aimed at targeting different aspects of tumor biology including proliferating and quiescent cancer stem cells, antitumor immunity, tumor–microenvironment interactions, cancer metabolism, and cancer-associated epigenetic modifications. Advancements of high-throughput molecular analyses keep unveiling new details of the CRC molecular landscape contributing to identifying novel targets, to define improved methods for patients’ classification and to achieve a better tuning of personalized therapies. Despite increasing knowledge of the molecular mechanisms underlying CRC, the percentage of new drugs that are obtaining clinical approval has been constantly decreasing in the last decades. The reason for this disconnection between basic/translational research and the related clinical outcomes resides, at least in part, in the limitations of preclinical models currently available for CRC. In fact, increasingly sophisticated experimental systems recapitulating CRC in vitro and in vivo, such as organoids and patient-derived xenografts are characterized by both intriguing complexities and intrinsic limitations, some of which are yet beginning to be understood. In this scenario, it is equally necessary to fully understand the potential of existing preclinical CRC models and to develop and validate novel tools for anticancer therapies. In this Special Issue, we will collect original research papers and reviews depicting the current state and the perspectives of CRC models for preclinical and translational research, examining and discussing their usefulness for patient diagnosis and therapy.

Dr. Marta Baiocchi
Dr. Ann Zeuner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma
Cancers 2020, 12(6), 1423; https://doi.org/10.3390/cancers12061423 - 31 May 2020
Cited by 1
Abstract
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in vitro culture models remain widely used, they allow only partial cell-to-cell and cell-to-matrix [...] Read more.
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in vitro culture models remain widely used, they allow only partial cell-to-cell and cell-to-matrix interactions and therefore do not represent the complex nature of the tumor microenvironment. Therefore, better models reflecting intra-tumor heterogeneity need to be incorporated in the drug screening process to more reliably predict the efficacy of drug candidates. Classic methods of modelling colorectal carcinoma (CRC), while useful for many applications, carry numerous limitations. In this review, we address the recent advances in in vitro CRC model systems, ranging from conventional CRC patient-derived models, such as conditional reprogramming-based cell cultures, to more experimental and state-of-the-art models, such as cancer-on-chip platforms or liquid biopsy. Full article
Show Figures

Figure 1

Back to TopTop